Literature DB >> 30773077

Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.

Elizabeth H Phillips1, Stephen Devereux2, John Radford3, Naheed Mir4, Toyin Adedayo1, Laura Clifton-Hadley1, Rod Johnson5.   

Abstract

Entities:  

Year:  2019        PMID： 30773077     DOI： 10.1080/10428194.2019.1576870

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  TLI in pediatric patients.

Authors:  A Ocanto; A Escribano; L Glaría; I Rodríguez; C Ferrer; C Huertas; A Pérez; R Morera
Journal:  Clin Transl Oncol       Date:  2019-09-21       Impact factor: 3.405

Review 2.  Novel targeted therapies of T cell lymphomas.

Authors:  Katarzyna Iżykowska; Karolina Rassek; Dorota Korsak; Grzegorz K Przybylski
Journal:  J Hematol Oncol       Date:  2020-12-31       Impact factor: 17.388
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.